Cargando…
Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers
The activating TERT promoter mutations and BRAF(V600E) mutation are well-established oncogenic alterations in human cancers. Coexistence of BRAF(V600E) and TERT promoter mutations is frequently found in multiple cancer types, and is strongly associated with poor patient prognosis. Although the BRAF(...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822828/ https://www.ncbi.nlm.nih.gov/pubmed/33483600 http://dx.doi.org/10.1038/s41698-020-00140-5 |
_version_ | 1783639713412808704 |
---|---|
author | Wu, Yongxing Shi, Liang Zhao, Yuelei Chen, Pu Cui, Rongrong Ji, Meiju He, Nongyue Wang, Maode Li, Gang Hou, Peng |
author_facet | Wu, Yongxing Shi, Liang Zhao, Yuelei Chen, Pu Cui, Rongrong Ji, Meiju He, Nongyue Wang, Maode Li, Gang Hou, Peng |
author_sort | Wu, Yongxing |
collection | PubMed |
description | The activating TERT promoter mutations and BRAF(V600E) mutation are well-established oncogenic alterations in human cancers. Coexistence of BRAF(V600E) and TERT promoter mutations is frequently found in multiple cancer types, and is strongly associated with poor patient prognosis. Although the BRAF(V600E)-elicited activation of ERK has been demonstrated to contribute to TERT reactivation by maintaining an active chromatin state, it still remains to be addressed how activated ERK is selectively recruited to mutant TERT promoter. Here, we report that transcription factor GABPA mediates the regulation of BRAF(V600E)/MAPK signaling on TERT reactivation by selectively recruiting activated ERK to mutant TERT promoter, where activated ERK can phosphorylate Sp1, thereby resulting in HDAC1 dissociation and an active chromatin state. Meanwhile, phosphorylated Sp1 further enhances the binding of GABPA to mutant TERT promoter. Taken together, our data indicate that GABPA and Sp1 synergistically activate mutant TERT promoter, contributing to tumorigenesis and cancer progression, particularly in the BRAF(V600E)-driven human cancers. Thus, our findings identify a direct mechanism that bridges two frequent oncogenic alterations together in TERT reactivation. |
format | Online Article Text |
id | pubmed-7822828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78228282021-01-29 Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers Wu, Yongxing Shi, Liang Zhao, Yuelei Chen, Pu Cui, Rongrong Ji, Meiju He, Nongyue Wang, Maode Li, Gang Hou, Peng NPJ Precis Oncol Article The activating TERT promoter mutations and BRAF(V600E) mutation are well-established oncogenic alterations in human cancers. Coexistence of BRAF(V600E) and TERT promoter mutations is frequently found in multiple cancer types, and is strongly associated with poor patient prognosis. Although the BRAF(V600E)-elicited activation of ERK has been demonstrated to contribute to TERT reactivation by maintaining an active chromatin state, it still remains to be addressed how activated ERK is selectively recruited to mutant TERT promoter. Here, we report that transcription factor GABPA mediates the regulation of BRAF(V600E)/MAPK signaling on TERT reactivation by selectively recruiting activated ERK to mutant TERT promoter, where activated ERK can phosphorylate Sp1, thereby resulting in HDAC1 dissociation and an active chromatin state. Meanwhile, phosphorylated Sp1 further enhances the binding of GABPA to mutant TERT promoter. Taken together, our data indicate that GABPA and Sp1 synergistically activate mutant TERT promoter, contributing to tumorigenesis and cancer progression, particularly in the BRAF(V600E)-driven human cancers. Thus, our findings identify a direct mechanism that bridges two frequent oncogenic alterations together in TERT reactivation. Nature Publishing Group UK 2021-01-22 /pmc/articles/PMC7822828/ /pubmed/33483600 http://dx.doi.org/10.1038/s41698-020-00140-5 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Wu, Yongxing Shi, Liang Zhao, Yuelei Chen, Pu Cui, Rongrong Ji, Meiju He, Nongyue Wang, Maode Li, Gang Hou, Peng Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers |
title | Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers |
title_full | Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers |
title_fullStr | Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers |
title_full_unstemmed | Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers |
title_short | Synergistic activation of mutant TERT promoter by Sp1 and GABPA in BRAF(V600E)-driven human cancers |
title_sort | synergistic activation of mutant tert promoter by sp1 and gabpa in braf(v600e)-driven human cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822828/ https://www.ncbi.nlm.nih.gov/pubmed/33483600 http://dx.doi.org/10.1038/s41698-020-00140-5 |
work_keys_str_mv | AT wuyongxing synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT shiliang synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT zhaoyuelei synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT chenpu synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT cuirongrong synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT jimeiju synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT henongyue synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT wangmaode synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT ligang synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers AT houpeng synergisticactivationofmutanttertpromoterbysp1andgabpainbrafv600edrivenhumancancers |